Artios pharma ltd

Artios Pharma Ltd: Revolutionizing Cancer Treatment with DDR Therapies

Artios Pharma Ltd is a leading independent DDR (DNA Damage Response) company that is dedicated to developing novel cancer therapies. The company has a strong pipeline of innovative drugs in development, which have the potential to be first-in-class and best-in-class treatments for various types of cancer.

The DNA Damage Response pathway plays a crucial role in maintaining genomic stability and preventing the development of cancer. Artios Pharma's focus on this pathway has led to the discovery of several promising drug candidates that target specific proteins involved in DDR signaling.

One such candidate is ART0380, an ATR inhibitor that has shown impressive preclinical activity against multiple tumor types. ATR inhibitors are a new class of drugs that selectively kill cancer cells by exploiting their reliance on the DDR pathway for survival. ART0380 is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors.

Another promising candidate from Artios' pipeline is POLθ inhibitor ART4215, which targets an enzyme involved in DNA repair processes. Preclinical studies have shown that inhibiting POLθ can sensitize cancer cells to chemotherapy and radiation therapy, making them more susceptible to treatment.

Artios Pharma's commitment to developing innovative therapies extends beyond its internal pipeline. The company also collaborates with other leading pharmaceutical companies and academic institutions to advance research into DDR-targeted therapies.

In 2020, Artios announced a collaboration with Merck KGaA, Darmstadt, Germany (not affiliated with Merck & Co., Inc., Kenilworth NJ USA), which will focus on discovering and developing small molecule inhibitors targeting key components of the DDR pathway. This partnership combines Artios' expertise in DDR biology with Merck's drug discovery capabilities and global reach.

Artios' team consists of experienced scientists who are passionate about advancing cancer treatment through cutting-edge science. The company was founded by Drs Simon Boulton, Graeme Smith, and Niall Martin in 2016, with the support of leading life science investors.

Artios Pharma's mission is to revolutionize cancer treatment by developing innovative DDR-targeted therapies that improve patient outcomes. With a strong pipeline of promising drug candidates and strategic collaborations with industry leaders, Artios is well-positioned to achieve this goal.